Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.

Uzun, SONER; Bilgiç Temel, ASLI; Akman Karakaş, AYŞE; Ergün, ERKAN; Özkesici, BİRGÜL; Eskiocak, ALİ; Erat, AYŞEGÜL; Uğurlu, NİLAY; Nazlım, BERNA; Koç, SALİHA; Bozkurt, SELEN; Dicle, ÖZLEM; Alpsoy, ERKAN; Yılmaz, ERTAN

doi:10.1111/ijd.13400

Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.

Uzun S., Bilgiç Temel A., Akman Karakaş A., Ergün E., Özkesici B., Eskiocak A. H., ...Daha Fazla

International journal of dermatology, cilt.55, sa.12, ss.1362-1368, 2016 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 55 Sayı: 12
Basım Tarihi: 2016
Doi Numarası: 10.1111/ijd.13400
Dergi Adı: International journal of dermatology
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1362-1368
Akdeniz Üniversitesi Adresli: Evet

Özet

BackgroundPemphigus vulgaris (PV) is a severe, chronic, and potentially life-threatening autoimmune blistering disease that affects the skin and mucous membranes. Rituximab is a monoclonal anti-CD20 antibody which has been used increasingly in the therapy of PV.